Last reviewed · How we verify
Lopinavir/ritonavir (drug)
Lopinavir/ritonavir is a combination protease inhibitor that blocks HIV protease, preventing viral replication by inhibiting the cleavage of viral polyproteins.
Lopinavir/ritonavir is a combination protease inhibitor that blocks HIV protease, preventing viral replication by inhibiting the cleavage of viral polyproteins. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, COVID-19 (investigational use in phase 3 trials).
At a glance
| Generic name | Lopinavir/ritonavir (drug) |
|---|---|
| Sponsor | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba |
| Drug class | HIV protease inhibitor combination |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Lopinavir is a potent HIV protease inhibitor that prevents the maturation of HIV virions by blocking the protease enzyme required to process viral proteins. Ritonavir is a second protease inhibitor included at low dose as a pharmacokinetic booster, inhibiting the metabolism of lopinavir and maintaining therapeutic plasma concentrations. Together, they reduce viral load and slow disease progression in HIV-infected patients.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- COVID-19 (investigational use in phase 3 trials)
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Headache
- Lipid abnormalities (elevated cholesterol/triglycerides)
- Hepatotoxicity
Key clinical trials
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Lopinavir/Ritonavir in PLWH With High-Grade AIN (PHASE1)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: